nanotech investing Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
nanotech investing Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
nanotech investing Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
nanotech investing Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
nanotech investing Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Skyharbour JV Partner Denison Mines Commences Winter Drill Program at the Wheeler North Joint Venture in Northern Saskatchewan
